Difference between revisions of "Ipatasertib (GDC-0068)"
Jump to navigation
Jump to search
(Created page with "=Mechanism of action= From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=669600 NCI Drug Dictionary]: An orally bioavailable inhibitor of the serine/...") |
Warner-admin (talk | contribs) m (Text replacement - "http://www.thelancet.com" to "https://www.thelancet.com") |
||
| Line 4: | Line 4: | ||
=Preliminary data= | =Preliminary data= | ||
==[[Breast cancer]]== | ==[[Breast cancer]]== | ||
| − | # Kim SB, Dent R, Im SA, Espié M, Blau S, Tan AR, Isakoff SJ, Oliveira M, Saura C, Wongchenko MJ, Kapp AV, Chan WY, Singel SM, Maslyar DJ, Baselga J; LOTUS investigators. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2017 Oct;18(10):1360-1372. Epub 2017 Aug 8. [ | + | # Kim SB, Dent R, Im SA, Espié M, Blau S, Tan AR, Isakoff SJ, Oliveira M, Saura C, Wongchenko MJ, Kapp AV, Chan WY, Singel SM, Maslyar DJ, Baselga J; LOTUS investigators. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2017 Oct;18(10):1360-1372. Epub 2017 Aug 8. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30450-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28800861 PubMed] |
=Also known as= | =Also known as= | ||
Revision as of 16:34, 20 May 2018
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Ipatasertib binds to and inhibits the activity of Akt in a non-ATP-competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis.
Preliminary data
Breast cancer
- Kim SB, Dent R, Im SA, Espié M, Blau S, Tan AR, Isakoff SJ, Oliveira M, Saura C, Wongchenko MJ, Kapp AV, Chan WY, Singel SM, Maslyar DJ, Baselga J; LOTUS investigators. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2017 Oct;18(10):1360-1372. Epub 2017 Aug 8. link to original article PubMed
Also known as
- Code names: GDC-0068, RG-7440